This retrospective case series evaluated partial splenic embolization (PSE) in 12 pediatric patients aged 8-15 years with hypersplenism secondary to portal hypertension at a tertiary care center in Colombia. No comparator group was reported. The intervention was associated with significant increases in hematological parameters: platelet count increased from a baseline median of 58,000 × 10⁹/L to 235,000 × 10⁹/L (p = 0.0004), and white blood cell count increased from 3,485 × 10⁹/L to 5,600 × 10⁹/L (p = 0.002). Among 8 patients who underwent endoscopic follow-up, 6 showed improvement in esophageal varices grade, though specific grading details were not reported.
Regarding safety, adverse events included transient abdominal pain and fever. No major adverse events such as splenic abscess, infarction, rupture, or hematoma were recorded. Discontinuations and tolerability were not reported.
Key limitations include the retrospective design, small sample size of only 12 patients, and single-center nature of the study. Follow-up duration was not reported, and the study lacked a comparator group for evaluating relative efficacy. The authors suggest PSE represents a minimally invasive alternative to splenectomy that preserves splenic function, but this descriptive analysis shows association only. Practice relevance is restrained by the low certainty evidence from this small, observational series without long-term outcomes or comparative data versus splenectomy.
View Original Abstract ↓
IntroductionEndovascular partial splenic embolization (PSE) represents a therapeutic alternative for managing portal hypertension and hypersplenism that preserves splenic parenchyma and maintains immune function. This study aimed to describe the therapeutic response and safety profile of PSE in pediatric patients treated over an eleven-year period at a tertiary care center in Colombia.MethodsThis was a descriptive, retrospective case series. We included 12 pediatric patients aged 8–15 years with hypersplenism secondary to portal hypertension who underwent PSE between 2012 and 2023 at our institution. Hematological parameters, endoscopic findings, and post-procedural complications were analyzed.ResultsThe median age was 13 years; nine patients (75%) had portal hypertension and hypersplenism due to portal vein thrombosis, and three (25%) due to hepatic fibrosis. The median percentage of embolized splenic parenchyma was 40% [IQR (25–60)]. Baseline platelet counts were 58,000 × 10⁹/L (50,250–67,000), and baseline leukocyte counts were 3,485 × 10⁹/L (2,728–4,090). Following PSE, statistically significant increases (delta) were observed in platelet count (median 235,000 × 10⁹/L, 95% CI 119,500–450,500; p = 0.0004) and white blood cell count (median 5,600 × 10⁹/L, 95% CI 2,883–8,925; p = 0.002). Eight patients underwent endoscopic follow-up; six demonstrated improvement in esophageal varices grade. Complications included transient abdominal pain and fever. No major adverse events, such as splenic abscess, infarction, rupture or hematoma, were recorded.ConclusionsIn our series, PSE demonstrated safety and efficacy in managing portal hypertension-related hypersplenism in pediatric patients, with significant improvements in hematological parameters and esophageal varices grade in most cases. PSE represents a valuable minimally invasive alternative to splenectomy, preserving splenic function while achieving therapeutic goals, even in patients requiring repeat interventions.